Thermo Fisher Scientific Inc

Thermo Fisher provides the tools and services that enable life sciences research, drug development, and clinical diagnostics. The company sells laboratory instruments (mass spectrometers, electron microscopes, genetic analyzers), consumables (reagents, plasticware, chemicals), and provides contract research, manufacturing, and clinical trial services to pharma and biotech clients. Revenue streams are diversified across four segments: analytical instruments, specialty diagnostics, life sciences solutions, and laboratory products/biopharma services, with roughly half from recurring consumables and services.

Thermo Fisher benefits from secular growth in biopharma R&D and an installed base generating recurring revenue through instrument service contracts and consumables. The company has a track record of accretive acquisitions and margin expansion. Risks include normalization from pandemic-era testing revenue peaks, exposure to biotech funding cycles, and integration challenges from large deals. The stock trades at a premium valuation reflecting its market leadership position, with growth tied to drug development activity and healthcare innovation spending.

Danaher competes across life sciences tools, diagnostics, and environmental/applied solutions with similar scale and margin profile. Agilent Technologies rivals Thermo in analytical instruments and lab consumables. Illumina dominates genetic sequencing where Thermo is a challenger. In contract services, Charles River Laboratories and IQVIA compete for pharma outsourcing spend. Competition varies significantly by product category given the broad portfolio.

Thermo Fisher pays a token dividend yielding around 0.3%, reflecting management's preference to deploy capital toward acquisitions and share buybacks rather than dividend growth. The company has increased the dividend modestly each year but maintains a very low payout ratio. This strategy aligns with the capital-intensive nature of the business and the M&A-driven growth model that has created shareholder value historically.

TMO last closed at $490.29, up 2.55% in the most recent trading session. Over the past 52 weeks, the stock has traded between a low of $385.46 and a high of $643.99. The current price represents 41% of its 52-week range, which helps investors gauge where the stock sits relative to its recent trading history.

Among 33 analysts covering TMO, the consensus rating is Strong Buy — 29 rate it a buy, 4 hold, and 0 sell. The average price target sits at $369.21, implying 25% downside from the current price. Keep in mind that analyst targets reflect 12-month expectations and can shift quickly after earnings reports or major company events.

Thermo Fisher Scientific Inc generated $43.49B in revenue during fiscal year 2026, with $6.54B reaching the bottom line as net income. The net profit margin of 15.0% is solid for its sector.

TMO trades at a P/E ratio of 26.13 on trailing earnings of $17.71 per share. That's roughly in line with the broader market average of ~20-25x. Comparing this multiple against Life Sciences Tools & Services sector peers gives better context than the broad market alone, since P/E norms vary significantly across industries.

Performance varies across timeframes, reflecting shifting market conditions. Returns by timeframe: -15.57% (3M), +5.61% (6M), -4.68% (1Y), -17.25% (YTD). Comparing these figures against the S&P 500 and sector benchmarks helps determine whether TMO is outperforming or lagging the broader market.